Zacks Investment Research upgraded shares of Affimed (NASDAQ:AFMD) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. Zacks Investment Research currently has $4.75 target price on the biopharmaceutical company’s stock.
According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “
AFMD has been the topic of a number of other reports. Leerink Swann initiated coverage on shares of Affimed in a research report on Thursday, March 28th. They set an outperform rating and a $4.17 price target on the stock. Svb Leerink initiated coverage on shares of Affimed in a research report on Thursday, March 28th. They set an outperform rating and a $8.00 price target on the stock. Finally, ValuEngine cut shares of Affimed from a buy rating to a hold rating in a research report on Friday, March 29th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $5.15.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.34. The firm had revenue of $25.96 million for the quarter. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%. As a group, equities analysts anticipate that Affimed will post -0.48 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. D. E. Shaw & Co. Inc. bought a new position in shares of Affimed during the fourth quarter worth $36,000. Lindbrook Capital LLC bought a new position in shares of Affimed during the fourth quarter worth $38,000. Geode Capital Management LLC boosted its position in shares of Affimed by 29.0% during the fourth quarter. Geode Capital Management LLC now owns 66,074 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 14,854 shares in the last quarter. Barclays PLC boosted its position in shares of Affimed by 35.6% during the fourth quarter. Barclays PLC now owns 76,959 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 20,196 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. lifted its position in Affimed by 16.1% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 26,480 shares in the last quarter. 41.07% of the stock is currently owned by institutional investors.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
See Also: Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.